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Abstract 
Background: Dr Nelson’s Improved Inhaler was first marketed with an advertisement 
in The Lancet in 1865. Revolutionary at the time for its ease of use and patient-
friendliness, the inhaler is still in use for self-treatment by many all over the world. On 
the occasion of its 150th anniversary, this study reports an experimental historical 
medicine approach to identify evidence for the quality of vapour inhalers.  
Methods: Through accessing reviews of the device’s use by the contemporary 
medical establishment, it was established that Dr Nelson’s Inhaler enjoyed a 
reputation of quality and efficacy among reputable physicians generating empirical 
evidence of clinical performance. There was a general absence of product 
performance tests during this period. Therefore, modern inhalation performance 
testing was applied to test the aerosol delivery performance for Friars’ Balsam, and 
its key chemical constituent, benzoic acid (BA).  
Results: A respirable dose of 59·9 ± 9·0 µg of BA was aerosolized in a 10 min period 
from a dose of 3·3 mL Friars’ Balsam (equivalent to 35·1 ± 0·2 mg of BA) in 375 mL 
of steaming water using the glass twin stage impinger at a flow rate of 60 Lmin-1. The 
respirable dose from a standardized aqueous BA inhalation formulation increased 
from 115·9 ± 10·6 µg to 200·2 ± 19·9 µg by increasing the simulated inhalation 
period from 5 min to 10 min. When tested with a simulated inhalation manoeuvre 
(500 mL tidal volume, 13 min-1 respiration rate, 1:2 inspiratory:expiratory ratio) a 
respirable dose of 112·8 ± 40·3 µg was produced.  
Conclusions: This work has highlighted the potential for aerosol drug delivery using 
steam inhalers that are popular with patients. Physicians should therefore be aware 
of the potential for lung dosing with irritants when patients self-medicate using the 
Nelson Inhaler with vaporizing formulations such as Friars’ Balsam.  
 
Keywords: Dr Nelson’s Inhaler; volatile inhalations; inhalation performance testing; 
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Introduction 
Inhaled therapies have been used for the treatment of pulmonary conditions and 
psychotropic effects for well over 4,000 years,1, 2 and the inhalation of vapours is 
documented in Egyptian, Indian, European, and East Asian texts. In the modern 
period, barring a few advocates, inhalation was a little-used route for administration 
of medicinal therapies until the early-19th century. Inhalation became increasingly 
noted as a therapeutic form in the late-18th century, first with Philip Stern advocating 
his own recipe of balsamic vapours in 1764,3 then John Mudge’s invention of a 
simple pewter inhaler in 1778 (seemingly the first use of the word ‘inhaler’ by a 
physician),4 and finally Thomas Beddoes and Humphry Davy’s experiments at the 
Pneumatic Institute in Bristol in the 1780s and 1790s.2, 5 British (Victorian) physician-
inventors were introduced to inhalation anaesthesia from Boston (US America) in 
1846-47, which served likewise to normalize perceptions of inhaled medicines and 
accelerate the exploitation of new materials (e.g. rubber and basic plastics) from the 
empires. This also helped to industrialize the production of steam-based inhalers and 
pneumatic atomizers which were at that stage being developed across France, 
Germany and Britain. Increasingly steam-based inhalers were being used for treating 
diseases like bronchitis, croup, and catarrh that accompanied the transition to 
industrial and urban modes of living.  
 
It was against this backdrop that the increasing awareness of pulmonary drug 
delivery in the medical press and the general demand for effective respiratory 
treatments congenially aligned in one of the least spectacular, but most successful 
pharmaceutical inventions of the period: Dr Nelson’s Ceramic Inhaler (Figure 1). The 
inhaler was presented at a meeting of the Royal Medical and Chirurgical Society on 
May 28th 1861.6 Its introduction to the market in 1865 by S. Maw & Son Co. from 
their London base in Aldersgate Street (following their introduction of various 
patented inhalers at the International Exhibition of 1862) heralded the acceptance in 
1867 of inhalants for the first time in the British Pharmacopoiea.7 Dr Nelson’s Inhaler 
was featured in The Lancet, The Medical Times and Gazette, and the British Medical 
Journal and became popular with self-medicators and professional physicians alike.2, 
8-12 Of the contemporary reviewers, William Abbotts Smith working in the Finsbury 
Dispensary and the Metropolitan Free Hospital (London), recommended the device 
on the back of empirical experience in a clinical environment.  
 Steam inhalers were replaced in conventional respiratory medicine by modern 
inhaler devices from the mid-20th century.13 However steam inhalations remained in 
popular use for ameliorating chronic bronchitis throughout the 20th century,14 and are 
recommended by healthcare practitioners across the world in the 21st century.15 Dr 
Nelson’s inhaler is still produced today, although it is now more usually used by 
singing coaches and performers including Ella Henderson, Sam Smith, and 
Professor Green.16-18 Vapour-steam inhalations are one of the most frequently self-
prescribed products for those with asthma19 as well as in other pulmonary conditions 
such as the common cold, although there is little available evidence to support this 
latter use.20 Indeed the risks of burns and scalds when using steam inhalations may 
outweigh any therapeutic benefit.21, 22  
 
Steam inhalations were not universally trumpeted and the effectiveness of the 
formulae of the British Pharmacopoeia was questioned in the academic press at the 
time.23 Hassall challenged the use of vapour inhalants based on meticulous 
experiments. In his critique he anticipated that there would be improvements to 
inhaler devices; however without the availability of modern analytical techniques, 
experimentation and device development were pragmatic and empirical. It is 
possible that the paucity of evidence for vapour inhalants arises from the poor quality 
standards and inability to test for their effectiveness at the height of their use, or 
device inefficiencies for otherwise effective medicaments. Indeed vapour inhalation 
has witnessed resurgence in recent years with the advent of e-cigarettes. With the 
use of vapour inhalations remaining common in self-administered pulmonary care, it 
is of interest to ask what modern analysis makes of the quality of vapour inhalers. 
Coinciding with the 150th anniversary of Dr Nelson’s Inhaler, the aim of this research 
was to examine whether an experimental history of science approach could offer 
evidence for the quality of historical therapies discounted by modern medicine.24 The 
approach included applying modern pharmaceutical performance testing of vapour 
inhalants of relevance to both historical and contemporary respiratory therapies.  
Methodology 
Experimental history of science approach 
The history of medical therapies focuses increasingly on the pragmatic and material 
dimensions of the subject,25-27 using both literary (e.g. journal articles, patents etc.) 
and non-literary components in its understanding of medical history. Pharmacy has 
always been a practical, hands-on form of production, experimentation, and 
provision of medical therapy, and is an ideal field in which to promote the 
experimental history of science approach. In terms of a history of pharmaceutical 
therapies, this means combining traditional methods of historical analysis (including 
the theoretical and conceptual knowledge recorded in pharmacopoeia and 
formularies, advertisements, prescriptions, medical publications and contemporary 
literature or popular press) with the identification of the experimental capabilities of 
the time (e.g. available analytical techniques), and the nature of pharmaceutical 
materials themselves (i.e. therapeutic use, efficacy and side-effects).28 For example, 
in one experimental approach medicines are reconstructed according to historical 
sources before being analysed according to current forms of analysis.29 In this 
respect vapour inhalations represent an excellent case study, since several 
remedies are still widely available as over-the-counter products or as (now-
regulated) herbal medicines of traditional use, which, although not allopathic, are still 
widely used in respiratory self-management.  
 
A survey of historical literature and correspondences relating to Dr Nelson’s Inhaler, 
the history of S. Maw and Sons, and clinical, commercial and advertising resources 
referring to the treatment of pulmonary diseases was conducted using online and 
print archival materials at the Bodleian Library, the Wellcome Library, the British 
Library, the Science Museum (London), and the BMJ Publishing Group Archives. 
These included the British Pharmacopoeia, Proceedings and Transactions of the 
learned societies including the Royal Medical and Chirurgical Society (now the Royal 
Society of Medicine), Royal College of Surgeons of Edinburgh, Royal College of 
Surgeons of England (RCSEng), reports on clinical studies, and medical handbooks 
for specialist and popular readership, historical advertisements, and medical 
ephemera.  
 
Survey of these textual sources furthermore enabled identification of historical 
medicaments widely in use, some of which (e.g. hydrocyanic acid) were disregarded 
as too toxic by contemporary standards to be considered worthwhile testing, leading 
to the choice of Friars’ Balsam for in-depth analysis. Although the actual preparation 
analysed was modern, comparison with historical instructions for preparation of 
ingredients (e.g. Tinctura Benzoini Composita in the British Pharmacopoeia of 1867) 
was important in the choice of analysed product. While some approaches to this 
experimental historical approach  attempt to recreate actual historical experimental 
and testing conditions, literary sources (as Hassal’s contemporary criticism shows) 
revealed a lack of any such stringent testing, meaning that the model of experimental 
history subsequently used in this study involved the deployment of modern testing 
methods. 
 
Experimental performance testing of Dr Nelson’s Inhaler 
A Dr Nelson’s Improved Inhaler (medium size) was purchased from John Bell & 
Croydon (London, UK) to assess the drug delivery performance of CareTM Friars’ 
Balsam (Thornton and Ross, Huddersfield, UK) in a glass twin stage impinger (TSI) 
(Copley Scientific Ltd., Nottingham, UK). This instrument enables the determination 
of the non-respirable (on Stage 1), and the respirable dose (i.e. the amount of drug 
emitted from an inhaler with an aerosol size below 6.4 µm, on Stage 2) of an 
inhalation product. Briefly, a standardized inhalation formulation was prepared 
containing 3.3 mL of Friars’ Balsam in 375 mL of steaming hot water (heated to 90 
°C). The latter concentration is in accordance with instructions to add 5 mL of 
tincture to 1 pint of water. The Inhaler was connected to the prepared TSI using a 
rubber adaptor, and the impinger was operated using an airflow rate of 60 Lmin-1 for 
10 min. The TSI was cooled for 30 min over ice, and maintained over ice to prevent 
post-deposition evaporation of the volatile components. Following completion of the 
standard ‘inhalation’, the dose of Friars’ Balsam emitted into the TSI was determined 
using a validated reversed phase high performance liquid chromatography (HPLC-
UV) method calibrated for the principal chemical component of Friars’ Balsam, 
benzoic acid (BA). Analytical standards of BA were purchased from Sigma Aldrich 
(Poole, UK), and HPLC-grade reagents (methanol, ethanol and ammonium acetate) 
were purchased from Fisher Scientific (Loughborough, UK). The Friars’ Balsam was 
itself standardized for BA content using the HPLC-UV quantification.  
 To assess the influence of patient use on the drug delivery performance, a 
standardized inhalation formulation of BA in hot water was prepared. A simulated 
tincture in accordance with the composition of the British Pharmacopoeia (2014) 
Benzoin Inhalation was prepared by dissolving BA in ethanol (1.875 g in 50 mL). 5 
mL of this solution was added to 375 mL steaming hot water as above. The drug 
delivery performance of the inhalant was assessed as above, but with operation of 
the TSI for 5 or 10 min duration, respectively. Finally, the most onerous test of the Dr 
Nelson’s Inhaler for delivery performance of the standardized BA formulation was 
performed using the Copley BRS 3000 inhalation simulator with a fast screening twin 
stage impactor (FSI) and mixing inlet (both from Copley Scientific, Nottingham, UK). 
The FSI was cooled with ice-packs for 30 min and maintained wrapped in ice-packs 
to prevent post-deposition evaporation of the volatile components. Rather than a 
continuous airflow, the ‘inhalation’ of a patient through the device was simulated 
using the Canadian Standard adult sinus breathing profile (500 mL tidal volume, 13 
min-1 respiration rate, 1:2 inspiratory:expiratory ratio) for a 10 min test period.30 The 
non-respirable and respirable doses of BA were determined by HPLC-UV, as above. 
In the case of the FSI, the respirable dose is retained on a glass-fibre filter trap, and 
corresponds to an aerosol size below 5 µm. 
 
Results  
Historical evidence of quality for Dr Nelson’s Inhaler 
At the conclusion of a meeting of the Royal Medical and Chirurgical Society (RMCS) 
on May 28th 1861, a certain Dr Nelson presented an inhaler (Figure 1), “its claims to 
notice being, great ease and simplicity of action; perfect cleanliness; and an 
arrangement of the mouthpiece by which is secured economy in the use of any 
medicated ingredient that may be required for inhalation”.6, 7 It is of interest that the 
presentation noted issues which remain of concern in modern inhalation therapy, 
namely the requirement for simplicity and ease of use by the patient to minimize 
errors of use. The inhaler was manufactured by Maw & Sons, a company at the 
forefront of manufacturing and supplying medical equipment to British hospitals and 
medical practitioners in Victorian Britain. Its reputation was such that it was featured 
in the 1862 Exhibition,7 where coincidentally a range of its ceramic inhalers were 
displayed.  
 The mid-19th Century is usually reconstructed with the narrative of Victorian Britons 
developing quality, safety and evidence concepts in medical therapy. For example, 
the Medicine Act of 1802 and the Apothecaries Act of 1815 exerted control over the 
practice of medicine. Likewise, the formation of the Pharmaceutical Society in 1841 
and the Pharmacy Act of 1868 limited the activity of apothecaries and druggists to 
registered individuals.31 However, despite this narrative, evidence of testing and 
regulating the efficacy of volatile medicaments (including those of the 
Pharmacopoeia) and related apparatuses is rare. In many cases, evidence can be 
derived from empirical findings gained through limited published medical case 
histories. Successful experiments by James Young Simpson in Edinburgh (1830s 
and 1840s) confirmed the ability to generate pharmacological affects by inhalation 
and Scudamore performed clinical trials of inhalation in respiratory patients “to show 
that they are capable of exerting a very important and beneficial influence in certain 
states of pulmonary and bronchial disease”.32 Albert Hill Hassall’s study in the BMJ 
(although notably, not including Dr Nelson’s Inhaler) criticised the efficacy of 3 of the 
5 Pharmacopoeia inhalations as being “infinitesimal, and may be said to be 
homeopathic”.23 It is notable that the designs of Dr Nelson’s Inhaler (Figures 1 and 2) 
lack many of the features which Hill Hassall criticised for the devices he tested, and 
device performance was also affected by the poor formulation design at the time. 
 
 
 
Experimental examination of the functional performance of Dr Nelson’s Inhaler  
HPLC analysis of the Friars’ Balsam revealed the content of benzoic acid (BA) in the 
proprietary product to be 10·64 ± 0·07 mg/mL of tincture (i.e. 1·06 % w/v). Therefore 
the total dose formulated as the steam inhalation was 35·11 ± 0·23 mg of BA. The 
twin stage impinger (TSI) contains a solvent trap to capture all aerosol which enters 
the apparatus. However, the performance testing revealed that only 130·8 ± 14·7 µg 
of BA was emitted from the Nelson’s Inhaler into the TSI as an aerosol (i.e. ~ 0·37 % 
of the total available BA dose). The dose of BA with an aerosol size suitable for 
deposition in the lungs (i.e. < 6·4 µm) was 59·95 ± 9·00 µg following 10 min of 
simulated inhalation at 60 Lmin-1. It is of note, that this corresponded to 45·7 ± 2·9 % 
of the total emitted aerosol. 
BA was selected as an appropriate marker compound for further mechanistic study, 
since it was the only compound appearing in the Friars’ Balsam HPLC-UV 
chromatograms that was also observed in the samples of aerosol depositing in the 
TSI. The deposition profile and performance metrics for steam aerosolization of the 
benzoic acid tincture are presented in Figure 3. The respirable dose (fine particle 
dose in Figure 3) was higher following 10 min compared to 5 min of operation 
(p<0.05), however the respirable fraction was unaffected by the aerosolization airflow 
(p>0.05 for 5 min versus 10 min of operation). This indicted that the aerosolization 
process would be consistent between patients, consistently delivering a high fraction 
suitable for deposition in the lungs of the user (~45 %).  
 
Operating the inhaler for 10 min at 60 Lmin-1 provided a statistically significant 
doubling of device efficiency and fine particle dose compared to 5 min operation, 
indicating that duration of inhalation and total inhaled volume are the key patient-use 
factors affecting the dose inhaler performance. Statistical analysis of the 
performance data (ANOVA and post-hoc Tukey’s testing) demonstrated no 
difference between the emitted dose, device efficiency or fine particle dose for the 5 
min (60 Lmin-1) and 10 min (sinus breathing) conditions, generally derived from the 
high variability in the simulated inhalation testing.  
 
 
 
Discussion 
This study sought to identify remedies employed during the age of the steam inhaler, 
on which basis, tincture of benzoin33 was chosen due to its widespread use as an 
expectorant at this period. The most commonly available form of this particular 
therapy to emerge from our literature review was Friars’ Balsam.1, 34 It is interesting 
that Friars’ Balsam as a volatile inhalant provides an unbroken link to the period 
when Dr Nelson’s Inhaler was invented. Although a prescribed therapy in the 19th 
Century, it retains a place as proprietary products in self-care and has an 
undiminished popular reputation. 
 
Despite the fact that there was a low overall efficiency of drug aerosolization from the 
inhaler, the fine particle fraction of the emitted dose (45·7 ± 2·9 %) compares 
favourably with many modern dry powder and pressurized metered dose inhalers. 
The key issue appeared to be the inefficiency of aerosol emission from the steam 
inhaler – an issue which could be addressed, for example, through improved 
entrainment and air-liquid mixing within a vapour device. The difference in throat and 
non-respirable deposition fractions for the TSI and FSI-breath simulator derive from 
the different construction of the test equipment. Nevertheless, using modern 
pharmaceutical performance testing approaches, it has proved possible to generate 
a dose of BA suitable for lung deposition from Friars’ Balsam using Dr Nelson’s 
Inhaler. 
 
 
When inhalations entered the British Pharmacopoeia of 1867, there was some 
scepticism as to their medical efficacy and safety. It is questionable whether the lack 
of clinical success for steam inhalations derived from the questionable pharmacology 
of the agents (e.g. hemlock), the poor delivery performance of the devices, or both.23, 
35  Dr Nelson’s Inhaler, on the other hand, is conspicuous by the clinical success it 
was said to have had. It was successful amongst professionals (one only needs to 
examine the variety of copies which emerged under various commercial brands over 
the years) and essentially ‘peer reviewed’: the clinical benefits of the device were 
praised by various physicians, from Spencer Thomson’s Dictionary of Domestic 
Medicine to William Abbotts Smith’s On Affections of the Throat and Lungs.11, 12 In 
this work, it has been demonstrated that Dr Nelson’s Inhaler can produce an 
inhalable dose of volatile organic agents typically employed (mainly) in self-care of 
respiratory infections, and hence a contribution has been made towards 
understanding its popularity amongst lay and medical communities in the second half 
of the 19th Century. 
 
Conclusion 
Some 150 years after the Dr Nelson’s Inhaler was introduced onto the market, this 
work has constructed historical evidence for the clinical efficacy and usability of the 
inhalation device in pulmonary medicine. Furthermore, it has demonstrated for the 
first time, using testing approaches unavailable when steam inhalers were being 
rejected by clinical medicine (1880-1900), proof of the delivery of a dose with 
properties suitable for deposition in the lungs. The findings of this article should not 
be construed as an attempt to ignite resurgence in the clinical use of volatile 
inhalants using Nelson’s inhaler. Nevertheless, clinicians should be aware of the 
potential for lung deposition in patients who self-medicate with steam inhalations that 
contain irritants such as benzoic acid, including with the Dr Nelson’s Inhaler.  
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